Evolutec Group plc (AIM: EVC), the biopharmaceutical company developing novel products for the treatment of allergic, inflammatory and autoimmune diseases, is pleased to announce the commencement of a 150 patient proof of concept Phase II trial with its lead compound, rEV131, against inflammation following cataract surgery. The trial will compare the anti-inflammatory effects of rEV131 versus prednisolone, the current standard of care, and placebo in post-operative inflammation of the anterior segment of the eye.
